Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Rockville, MD (PRWEB) July 29, 2014 ... (ITI), a vaccine pioneer in the biotechnology industry, ... firm Newport Coast Securities, Inc. to explore financing ... commercializing LAMP-vax technology, a breakthrough vaccine platform with ... immunotherapy market. The company exclusively licensed the well-established ...
(Date:7/29/2014)... VONORE, Tenn. (PRWEB) July 29, 2014 ... leader in biomass feedstock supply innovation and supply ... new proprietary feedstock management systems, Energy Grangeā„¢ and ... years of R&D and in-the-field testing aimed at ... and offering benefits to landowners, farmers and feedstock ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 DisasterTalk is a ... people where cell phone masts or other transmitters are down. ... 100 feet away without the need for any Wi-Fi, and ... ranges. , The new app has launched as a ... are at very high risk of being affected by natural ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... Pharmaceutical and ... Biotech Industries, ... short-term and long-term biomaterials storage, sample,management and cold chain logistics, ... inaugural,Biorepositories 2008, the only U.S.-based event for the pharmaceutical and,biotech ...
... portfolio, CORAL GABLES, Fla., June 23 ... pharmaceutical company specializing in,dermatology, today announced it ... which Stiefel Laboratories will acquire Barrier Therapeutics,Inc. ... a two-step,transaction, a tender offer followed by ...
... JOLLA, Calif., June 23 TorreyPines Therapeutics,Inc. (Nasdaq: ... Kurtz, President and,Chief Executive Officer, will present data ... safety, tolerability and efficacy of three doses,of tezampanel ... the,50th Annual Scientific Meeting of the American Headache ...
Cached Biology Technology:BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008 2Barrier Therapeutics to Merge Into Stiefel Laboratories 2Barrier Therapeutics to Merge Into Stiefel Laboratories 3Barrier Therapeutics to Merge Into Stiefel Laboratories 4Barrier Therapeutics to Merge Into Stiefel Laboratories 5TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society 2
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... Research and Markets  has announced the ... Market 2014-2018" report to their offering. ... term BI refers to applications and technologies that are ... about a company,s operations. BI help organizations to acquire ... example, metrics on sales, production, and internal operations. ...
(Date:7/29/2014)... Swimming microorganisms, such as bacteria and spermatozoa, are subjected ... forces exerted by the surrounding fluid. Such low-level ... found that the direction of propulsion made possible by ... viscoelastic fluid. These findings have been published in ... Energies and Atomic Energy Commission (CEA), in Le Barp, ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Optimum inertial self-propulsion design for snowman-like nanorobot 2
... to interact with the genes her unborn child inherits and ... research funded by the Wellcome Trust and the British Heart ... Molecular Genetics , suggests that mothers who eat a high ... the health of their offspring at risk. Congenital heart ...
... a new means of determining the sex of skeletal human ... the wake of disasters, the studying of ancient remains and ... able to determine the sex of skeletal remains by visually ... coxa. "This technique is accurate, but is not without its ...
... Ga. - Robots that revolutionized gynecologic and urologic surgery in ... least a portion of their diseased thyroid gland without the ... just under the Adam,s apple and controls the body,s metabolic ... cancerous disease can more than double its size. Dr. David ...
Cached Biology News:Maternal diet and genes interact to affect heart development 2Maternal diet and genes interact to affect heart development 3Hips don't lie: Researchers find more accurate technique to determine sex of skeletal remains 2Robots preclude neck incision for thyroid surgery 2
Request Info...
... Power Supply, 1. 3500 V, 400 mA, ... power, and linear voltage ramp modes.Linear voltage ... in IPG strips quickly without danger of ... in gel thickness, sample ionic strength, and ...
MOUSE ANTI BOVINE CD335:ALEXA 488 Immunogen: Fusion protein consisting of the extracellular region of bovine CD335....
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Biology Products: